1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Avivagen Inc.

Avivagen Inc.

VIVXF
Avivagen Inc.US flagOther OTC
0.00
USD
- -
- -
7,769.00Market Cap
Avivagen Inc.
VIVXF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
0.17
0.19
0.53
0.05
0.05
0.05
0.01
0.02
0.01
- -
0.01
0.03
0.03
0.03
0.02
0.01
0.01
Revenue per Share
-0.5
-0.57
-0.6
-0.81
-0.66
-0.24
-0.18
-0.12
-0.1
-0.12
-0.18
-0.15
-0.14
-0.12
-0.12
-0.09
-0.06
Basic EPS, GAAP
-0.6
-0.3
-0.51
-0.64
-0.35
-0.25
-0.23
-0.1
-0.08
-0.1
-0.16
-0.12
-0.11
-0.08
-0.09
-0.05
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.08
-2.52
-3.1
-2.82
-2.48
-1.83
-1.53
-1.14
-0.78
-0.78
-0.09
-0.1
-0.21
-0.21
-0.16
-0.16
-0.16
Book Value per Share
-0.01
-0.52
-0.49
-0.88
-0.81
-0.51
-0.17
-0.14
0.02
0.16
0.01
- -
-0.09
-0.12
-0.08
-0.09
-0.12
Tangible Book Value per Share
2
2
2
3
5
8
11
17
19
22
29
33
34
40
52
66
77
Basic Weighted Avg Shares
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Sales/Revenue/Turnover
-281.68
-317.36
-110.15
-1,430.72
-1,020.25
-467.84
-1,819.9
-705.43
-1,222.18
-24,701.37
-1,882.25
-386.82
-398.27
-287.56
-104.76
-163.3
119.11
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-1
-3
-4
-2
-2
-2
-2
-3
-5
-5
-5
-5
-6
-6
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-289.11
-307.81
-113.61
-1,506.02
-1,213.17
-472.69
-1,831.41
-703.62
-1,222.18
-25,994.26
-2,008.79
-450.7
-494.8
-403.38
-493.38
-645.91
-648.74
Profit Margin (%)
- -
- -
1
-1
-2
-1
1
1
- -
5
1
2
- -
-1
-3
-1
-8
Working Capital
1
1
- -
- -
- -
- -
- -
- -
- -
1
1
2
4
5
1
5
1
LT Debt
- -
-1
-1
-2
-4
-4
-2
-2
- -
4
- -
- -
-3
-5
-4
-6
-9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jan'23
Apr'23
Jul'23
ST Debt
1
5
6
LT Borrowings
5
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
77
78
78
Market Capitalization
76
21
11

Working Capital

FRC

•

in mil. unless spec.
Jan'23
Apr'23
Jul'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
7
8
Payables & Accruals
1
2
2
ST Debt
1
5
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-298.16%
-707.19%
51.39%
Free Cash Flow
11.01%
-5.61%
-32.36%
Net Income, GAAP
14.76%
4.37%
-5.13%
Sales/Revenue/Turnover
259.15%
62.73%
-27.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
1
- -
1
2022
- -
- -
- -
1
1
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.03
-0.04
-0.02
- -
-0.12
2022
-0.03
-0.02
-0.03
- -
-0.09
2023
-0.01
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Ecofibre Limited (EOF.AX)
Hikma Pharmaceuticals PLC (HKMPY)
Glenmark Pharmaceuticals Limited (GLENMARK.NS)
Evotec SE (EVOTF)
Benchmark Holdings plc (BHCCF)
Evotec SE (EVT.DE)
Business
Avivagen Inc. (VIVXF) is a Canada-based life sciences company that develops and commercializes health products for livestock, companion animals and humans utilizing its proprietary OxC-beta technology, a first-in-class source of beta-carotene-oxygen copolymer compounds offering non-vitamin A benefits such as enhanced immune function, improved growth performance and reduced reliance on antibiotics in animal feeds; core products include OxC-beta Livestock for swine, poultry and dairy applications, Vivamune Vital Health Chews and Oximunol Chewable Tablets for companion animals. Founded in 2005 and headquartered at 100 Sussex Drive in Ottawa, Ontario, the company operates primarily in North America with distribution and trials extending to Australia, Brazil, Mexico and other regions in the Americas, targeting livestock producers, pet owners and potentially human wellness markets through its biotechnology platform. Recent developments include board changes in 2023 with David Hankinson appointed as Chair and Kym Anthony as Vice-Chair following the departure of Jeffrey Kraws and Aubrey Dan, alongside ongoing commercial expansions such as a 1.2-tonne order from AB Vista for poultry and cattle trials in Brazil, dairy sector agreements in Mexico demonstrating improved milk quality, and cumulative usage of OxC-beta in approximately 16 million piglets, 94,000 sows, 19.6 million poultry and 12,000 dairy cows as of mid-2022, though the company faced financial challenges including a voluntary assignment into bankruptcy proceedings announced around 2023-2024.

Company News

APIChatGPT

  • defenseworld.net

    High Tide (NASDAQ:HITI) and Avivagen (OTCMKTS:VIVXF) Financial Comparison

  • defenseworld.net

    Contrasting Avivagen (OTCMKTS:VIVXF) & Stryker (NYSE:SYK)

  • newsfilecorp.com

    Avivagen Makes Voluntary Assignment into Bankruptcy Under the BIA

  • businesswire.com

    Avivagen Announces New 500Kg Order for OxC-beta™

  • businesswire.com

    Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2023

  • businesswire.com

    Avivagen Provides Corporate Updates

  • businesswire.com

    Avivagen Announces New Orders for 1.1 Tonnes of Oxc-Beta™ Livestock Product

  • businesswire.com

    Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

  • businesswire.com

    Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2021

  • businesswire.com

    Avivagen Announces Largest Single Customer Purchase Order

  • businesswire.com

    Avivagen Inc. to Issue Shares to Holders of Debentures in Lieu of Annual Maintenance Fee

  • newsfilecorp.com

    Avivagen Discusses Significant Purchase Orders for OxC-beta(TM) Livestock with The Stock Day Podcast